Samples Of Antibiotics Found Fake In Testing

Ghaziabad : Samples of three antibiotics have failed in the quality tests. These include Zifi 200, Augmentin 625 and Clavam 625 medicines sold in the name of renowned companies. The officials of the FSDA will now take action by finding out the racket behind these fake medicines. Action will also be taken against the medical store operators.

Drug Inspector Ashutosh Mishra said that these samples were taken from Rana Medicos in Dasna in November. They were sent for testing. Recently their test report has been received in which the samples of all the three medicines were found to have failed in quality tests. The active ingredients which should have been there in the medicines were not found. It shows fake medicines were being sold in the market in the name of these companies.

Drug Inspector Ashutosh Mishra told that there is a passcode on the medicine named Zifi 200 mg, through which it was known that it is fake. On the basis of this, a report was filed against the medical store Mohammad Ismail in November itself and his arrest was made. The court sent him to jail. Now after the test report arrives, another case will be registered, in which the punishment can be up to life imprisonment.

The drug named Zifi is manufactured by M/s FDC Ltd. and its plant is located in Baddi Solan, Himachal Pradesh. The drug named Clavam is manufactured by a Sikkim-based company named Alkem Health Science and Augmentin drug is marketed by a company named Glaxo. FSDA officials say that the names of well-known companies were written on the packets of these fake medicines like real medicines. So that the buyers get into the trap.

  • Related Posts

    • Pharma
    • June 24, 2025
    • 72 views
    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

    • Pharma
    • June 24, 2025
    • 74 views
    India’s herbal and ayurvedic OTC market set to outpace global growth

    New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India

    India’s herbal and ayurvedic OTC market set to outpace global growth

    India’s herbal and ayurvedic OTC market set to outpace global growth

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug